Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
A Better NSAID: NicOx<br />
• Naproxcinod is a derivative of naproxen with similar anti-inflammatory activity, but less<br />
gastrointestinal side effects. It is <strong>the</strong> first of a new class of analgesic and antiinflammatory<br />
drugs known as cyclo-oxygenase-(COX)-inhibiting nitric oxide donators<br />
(CINODs).<br />
• The improved gastrointestinal tolerability of naproxcinod appears to be due to its<br />
release of nitric oxide (NO) and <strong>the</strong> consequent maintenance of tissue perfusion and<br />
integrity. Data to date also suggests that naproxinod may also have a beneficial and<br />
sustained impact on blood pressure.<br />
• Naproxcinod is in Phase III clinical development in Europe, <strong>the</strong> US and Canada for <strong>the</strong><br />
treatment of osteoarthritis. NDA filing is projected for mid-2009.<br />
Adis R&D Insight; NicOx <strong>presentation</strong><br />
23<br />
© Defined Health, 2009<br />
Pain Insight Briefing